Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

Similar articles for PubMed (Select 23442176)

1.

Quantitative proteomic analysis identified paraoxonase 1 as a novel serum biomarker for microvascular invasion in hepatocellular carcinoma.

Huang C, Wang Y, Liu S, Ding G, Liu W, Zhou J, Kuang M, Ji Y, Kondo T, Fan J.

J Proteome Res. 2013 Apr 5;12(4):1838-46. doi: 10.1021/pr3011815. Epub 2013 Mar 5.

PMID:
23442176
2.

Proteomic profiling of N-linked glycoproteins identifies ConA-binding procathepsin D as a novel serum biomarker for hepatocellular carcinoma.

Qi YJ, Ward DG, Pang C, Wang QM, Wei W, Ma J, Zhang J, Lou Q, Shimwell NJ, Martin A, Wong N, Chao WX, Wang M, Ma YF, Johnson PJ.

Proteomics. 2014 Feb;14(2-3):186-95. doi: 10.1002/pmic.201300226.

PMID:
24259486
3.

Glutamine synthetase as an early marker for hepatocellular carcinoma based on proteomic analysis of resected small hepatocellular carcinomas.

Long J, Lang ZW, Wang HG, Wang TL, Wang BE, Liu SQ.

Hepatobiliary Pancreat Dis Int. 2010 Jun;9(3):296-305.

4.
5.

Proteomics of hepatocellular carcinoma: serum vimentin as a surrogate marker for small tumors (<or=2 cm).

Sun S, Poon RT, Lee NP, Yeung C, Chan KL, Ng IO, Day PJ, Luk JM.

J Proteome Res. 2010 Apr 5;9(4):1923-30. doi: 10.1021/pr901085z.

PMID:
20121168
6.

Serum paraoxonase 1 heteroplasmon, a fucosylated, and sialylated glycoprotein in distinguishing early hepatocellular carcinoma from liver cirrhosis patients.

Sun C, Chen P, Chen Q, Sun L, Kang X, Qin X, Liu Y.

Acta Biochim Biophys Sin (Shanghai). 2012 Sep;44(9):765-73. doi: 10.1093/abbs/gms055. Epub 2012 Jul 1.

PMID:
22751611
7.

Predictor for histological microvascular invasion of hepatocellular carcinoma: a lesson from 229 consecutive cases of curative liver resection.

Eguchi S, Takatsuki M, Hidaka M, Soyama A, Tomonaga T, Muraoka I, Kanematsu T.

World J Surg. 2010 May;34(5):1034-8. doi: 10.1007/s00268-010-0424-5.

PMID:
20127241
8.

Identification of serum monocyte chemoattractant protein-1 and prolactin as potential tumor markers in hepatocellular carcinoma.

Wang WW, Ang SF, Kumar R, Heah C, Utama A, Tania NP, Li H, Tan SH, Poo D, Choo SP, Chow WC, Tan CK, Toh HC.

PLoS One. 2013 Jul 18;8(7):e68904. doi: 10.1371/journal.pone.0068904. Print 2013.

9.

Predictors of microvascular invasion before hepatectomy for hepatocellular carcinoma.

Kaibori M, Ishizaki M, Matsui K, Kwon AH.

J Surg Oncol. 2010 Oct 1;102(5):462-8. doi: 10.1002/jso.21631.

PMID:
20872949
10.

A proteomic strategy to identify novel serum biomarkers for liver cirrhosis and hepatocellular cancer in individuals with fatty liver disease.

Gray J, Chattopadhyay D, Beale GS, Patman GL, Miele L, King BP, Stewart S, Hudson M, Day CP, Manas DM, Reeves HL.

BMC Cancer. 2009 Aug 5;9:271. doi: 10.1186/1471-2407-9-271.

11.

Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors.

Sumie S, Kuromatsu R, Okuda K, Ando E, Takata A, Fukushima N, Watanabe Y, Kojiro M, Sata M.

Ann Surg Oncol. 2008 May;15(5):1375-82. doi: 10.1245/s10434-008-9846-9. Epub 2008 Mar 7.

PMID:
18324443
12.

Microvascular invasion (MVI) is a poorer prognostic predictor for small hepatocellular carcinoma.

Du M, Chen L, Zhao J, Tian F, Zeng H, Tan Y, Sun H, Zhou J, Ji Y.

BMC Cancer. 2014 Jan 24;14:38. doi: 10.1186/1471-2407-14-38.

13.

Identification of transaldolase as a novel serum biomarker for hepatocellular carcinoma metastasis using xenografted mouse model and clinic samples.

Wang C, Guo K, Gao D, Kang X, Jiang K, Li Y, Sun L, Zhang S, Sun C, Liu X, Wu W, Yang P, Liu Y.

Cancer Lett. 2011 Dec 27;313(2):154-66. doi: 10.1016/j.canlet.2011.08.031. Epub 2011 Oct 8.

PMID:
22023829
14.

Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study.

Poon RT, Ng IO, Lau C, Zhu LX, Yu WC, Lo CM, Fan ST, Wong J.

Ann Surg. 2001 Feb;233(2):227-35.

15.

Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinicopathologic features in human hepatocellular carcinoma.

Yao DF, Wu XH, Zhu Y, Shi GS, Dong ZZ, Yao DB, Wu W, Qiu LW, Meng XY.

Hepatobiliary Pancreat Dis Int. 2005 May;4(2):220-6.

16.

Differential proteomics identification of HSP90 as potential serum biomarker in hepatocellular carcinoma by two-dimensional electrophoresis and mass spectrometry.

Sun Y, Zang Z, Xu X, Zhang Z, Zhong L, Zan W, Zhao Y, Sun L.

Int J Mol Sci. 2010 Mar 31;11(4):1423-33. doi: 10.3390/ijms11041423.

17.

Relationship between serum heparanase and microscopic venous invasion in patients with hepatocellular carcinoma.

Wang GB, Zhou XY, Wang XQ.

Am J Clin Pathol. 2010 Aug;134(2):242-8. doi: 10.1309/AJCPPJM6VHG4LPJX.

18.

Identification of cystatin B as a potential serum marker in hepatocellular carcinoma.

Lee MJ, Yu GR, Park SH, Cho BH, Ahn JS, Park HJ, Song EY, Kim DG.

Clin Cancer Res. 2008 Feb 15;14(4):1080-9. doi: 10.1158/1078-0432.CCR-07-1615.

19.

Quantitative proteomic signature of liver cancer cells: tissue transglutaminase 2 could be a novel protein candidate of human hepatocellular carcinoma.

Sun Y, Mi W, Cai J, Ying W, Liu F, Lu H, Qiao Y, Jia W, Bi X, Lu N, Liu S, Qian X, Zhao X.

J Proteome Res. 2008 Sep;7(9):3847-59. doi: 10.1021/pr800153s. Epub 2008 Jul 23.

PMID:
18646787
20.

Toward the proteomic identification of biomarkers for the prediction of HBV related hepatocellular carcinoma.

He QY, Zhu R, Lei T, Ng MY, Luk JM, Sham P, Lau GK, Chiu JF.

J Cell Biochem. 2008 Feb 15;103(3):740-52.

PMID:
17557278
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk